v3.26.1
Significant agreements - Novartis Collaboration Agreement (Details)
$ in Thousands
1 Months Ended 12 Months Ended
Mar. 27, 2023
USD ($)
item
Nov. 30, 2025
USD ($)
Nov. 30, 2024
USD ($)
Dec. 31, 2025
USD ($)
Dec. 31, 2024
USD ($)
Dec. 31, 2023
USD ($)
Significant agreements.            
Revenue from collaborative arrangement       $ 72,586 $ 35,275 $ 26,976
Deferred revenue       $ 38,469 101,658 135,194
Maximum Days Allowed for Cancellation of Contracts Prior Written Notice       90 days    
Novartis            
Significant agreements.            
Number of collaboration targets | item 2          
Payment received $ 50,000          
Transaction price $ 50,000   $ 53,000      
Revenue from collaborative arrangement   $ 41,900   $ 46,985 8,161 1,909
Deferred revenue       $ 0 44,073 $ 50,008
Amount of estimate of variable consideration     $ 3,000      
Novartis | Two material rights associated with limited substitution rights            
Significant agreements.            
Number of material rights | item 2          
Novartis | Two material rights associated with options to progress development candidates incorporating radionuclides            
Significant agreements.            
Number of material rights | item 2          
Novartis | Two material rights associated with options to progress development candidates not incorporating radionuclides            
Significant agreements.            
Number of material rights | item 2          
Novartis | Expiration of two material rights associated with limited substitution rights            
Significant agreements.            
Revenue from collaborative arrangement         $ 2,500